Investor Presentation Q1 2018

B-cell function Investor Presentation First three months of 2018 Slide 38 Insulin is the ultimate care for people with diabetes Progression of type 2 diabetes and treatment intensification Distribution of patients and value across treatment classes Diet and exercise OAD: Oral anti-diabetic changing diabetes Time OAD GLP-1 100% Insulin GLP-1 80% 38% 68% 60% 13% 40% Insulin 5% 49% 20% 27% 0% Patients Value Note: Patient distribution across treatment classes is indicative and based on data for US, UK, Germany and France. Value figures based on IQVIA MAT Feb, 2018 Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS OAD novo nordisk

View entire presentation